CORDIS
EU research results

CORDIS

English EN

Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis

Project information

Grant agreement ID: 258677

Status

Closed project

  • Start date

    1 January 2011

  • End date

    30 June 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 849 117,33

  • EU contribution

    € 2 965 749

Coordinated by:

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

Spain

Objective

Lung cancer (LC) is still the most lethal type of cancer worldwide. The extremely poor prognosis for LC patients is partly due to the lack of effective therapies. At present, most patients with pulmonary carcinomas are treated with chemotherapy. This essentially consists of classic cytotoxic drugs which only improve survival in small cohorts in few cases. In spite of the rapidly growing understanding of the epigenetic and genetic profile of LC, such knowledge has contributed little to improving therapeutics. This scenario, however, is likely to change soon because several specific cancer therapies, targeting molecules that are altered in cancer, are being developed or are already undergoing clinical trials. Thinking ahead, our proposal focuses, on the one hand, on validating novel and specific therapeutic strategies, with particular emphasis on discovering (epi)genetic alterations that could act as novel targets for therapies, and, on the other, on defining the (epi)genetic markers that could determine the efficacy response or resistance to targeted therapies as well as the acquired resistance of the tumours to therapy. To reach our goals, we have designed an integrative and interdisciplinary approach involving leading European clinical scientists of international renown with prominent preclinical and basic research groups using high throughput and state-of-the art platforms for genomics and gene expression analysis. To date, no such comprehensive information exists. The results will be of great value for the stratification of lung tumours according to their genetic background for tailored treatments. The development of an (epi)genetic-based therapeutic prediction model will hopefully set the basis for future tailored treatment of LC as well as of other epithelial cancers.

Coordinator

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

Address

Avenida Gran Via Hospitalet 199-203
08908 L'Hospitalet De Llobregat

Spain

Activity type

Research Organisations

EU Contribution

€ 798 520

Administrative Contact

Verónica Padial (Mrs.)

Participants (10)

THE UNIVERSITY OF LIVERPOOL

United Kingdom

EU Contribution

€ 298 370

UNIVERSITE JOSEPH FOURIER GRENOBLE 1

France

EU Contribution

€ 279 600

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA

Spain

EU Contribution

€ 280 024

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 73 119,82

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

Italy

EU Contribution

€ 279 000

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 200 400

INSTITUT GUSTAVE ROUSSY

France

EU Contribution

€ 150 000

KLINIKUM DER UNIVERSITAET ZU KOELN

Germany

EU Contribution

€ 332 380,18

Krzysztof Kucharczyk Techniki Elektroforetyczne Spzoo

Poland

EU Contribution

€ 149 370

MRC HOLLAND B.V.

Netherlands

EU Contribution

€ 124 965

Project information

Grant agreement ID: 258677

Status

Closed project

  • Start date

    1 January 2011

  • End date

    30 June 2014

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 849 117,33

  • EU contribution

    € 2 965 749

Coordinated by:

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

Spain